BioNTech Results Presentation Deck

Vaccine Efficacy Remains High up to 6 Months Following 2nd Dose ¹,2 Pivotal Phase 3 trial: ~46,000 participants, ~150 clinical sites globally Subjects >12 Years of Age* BNT162b2 (30 µg) N=23,040 Efficacy Endpoint First COVID-19 15 occurrence ≥7 days after Dose 2 First Severe COVID-19+ occurrence ≥7 days after Dose 2 No. of cases 82 1 Surveillance time (n)t 6.649 (22,132) 6.663 (22,142) *Subjects with and without prior evidence of Infection + Based on FDA definitions No. of cases 889 Placebo N=23,037 23 Surveillance time (n)t 6.371 (22,001) 6.505 (22,048) Vaccine Efficacy, (95% CI) ¹Thomas SJ et al. medRxiv Preprint, July 29, 2021. Available at https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf. 2https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-confirm-high-efficacy-and-no-serious-safety accessed June2021 91.2% (88.9-93.0) EN Phase 3 Clinical data demonstrated clinical protection against the Beta strain² In 800 South African participants: 9 COVID-19 cases, all in the placebo group, eight of which were the B.1.351 variant 95.7% (73.9-99.90) BIONTECH

View entire presentation